Article Details

Takeda, CSL to end alliance as plasma-based COVID-19 drug fails key test

Retrieved on: 2021-04-05 15:35:23

Tags for this article:

Click the tags to see associated articles and topics

Takeda, CSL to end alliance as plasma-based COVID-19 drug fails key test. View article details on hiswai:

Excerpt

Because convalescent plasma is taken from individuals, its therapeutic punch can be highly variable and depend on the levels of antibodies in each ...

Article found on: www.biopharmadive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up